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Abstract 
 
Objective: The objective of this selective EBM review is to determine where or not “Are Cox-2 
inhibitors such as celecoxib and parecoxib effective in reducing post-tonsillectomy pain?” 
 
Study Design: Review of three double blind randomized controlled trials (RTC). 
 
Data Sources: All studies were published in peer-reviewed journals found via the use of 
PubMed. 
 
Outcomes Measured: Patients were divided into two groups: those who received the Cox-2 
inhibitor and those who received the placebo, in order to measure postoperative pain using 
patient or parent reported journals or diaries, questionnaires, and various pain scales (CHEOPS, 
and WP24HR with VAS). 
 
Results: Two out of three studies show a modest, but clinically significant decrease in pain post 
tonsillectomy with or without adenoidectomy.  However, one study did not show a change in 
pain scores between the Cox-2 group and the placebo.  Using parecoxib as the drug, Li X 
showed Group P had significantly lower CHEOPS scores than Group S (7 [5-8] vs. 9 [8-11] 
respectively.  P=0.001).  Murto et al showed the celecoxib group resulted in an 11% reduction in 
WP24HR score averaged over POD 0-2 (95% CI: 0.3-14.  P=0.04) and additionally a 14% 
increase in WP24HR pain scores on POD 3 after the cessation of the intervention.  Van Daele et 
al did not show a statistically significant decrease in pain between the two groups even though 
the scores for the intervention group were generally lower than the placebo.   
 
Conclusions: Two out of the three randomized controlled trials studied reported statistically 
significant decrease in pain post tonsillectomy with or without adenoidectomy in the intervention 
group versus the placebo.  Van Daele et al concluded that there was no statistical significant 
decease in pain between the two groups, however, this study used patients eighteen and older, 
which varied from the other studies.  With this information it can be concluded that in children 
aged two to eighteen, Cox-2 inhibitors do show a statistically significant decrease in pain post 
tonsillectomy.  Further studies are warranted in order to determine significance in an older 
patient population. 
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Introduction 
Tonsils are two clusters of soft tissue located on both sides of the posterior throat.  
Tonsillectomies are a surgical procedure used to remove the tonsils for various reasons including 
recurrent tonsillitis, recurrent pharyngitis, and obstructive sleep apnea1.  Over the years much has 
changed in terms of procedure, guidelines, and recovery.  In 2011, American Academy of 
Otolaryngology released a clinical practice guideline to help physicians and parents better 
understand the indications of surgery and to better optimize the before and after care of patients 
undergoing a tonsillectomy2.  Every patient undergoing a tonsillectomy experiences post-
operative pain that is monitored and treated appropriately.  Cyclooxygenase-2 (Cox-2) inhibitors 
are a type of NSAID that selectively blocks only the Cox-2 enzyme, which is usually responsible 
for the pain and swelling associated with inflammation3.  These drugs are different than other 
NSAIDs, which block both Cox-1 and Cox-2 enzymes.  In previous studies, 15 out of 20 have 
shown that when used preoperatively, COX-2 inhibitors, specifically celecoxib, are better with 
postoperative pain as compared to a placebo4. This paper evaluates three double blind 
randomized controlled trials that compare the efficacy of celecoxib and parecoxib  (Cox-2 
inhibitors) as medication to reduce post-operative pain after a tonsillectomy.   
This topic is relevant to the PA scope of practice because it is important for a PA to 
determine the indications for surgery, and how to care for patents pre- and post -operatively.  In 
the United States, tonsillectomies are the 3rd most common procedure performed on children or 
about 530,000 a year, 186,000 being performed on patients 15 years or older4.  Patients aged 15 
or younger make up 20% of all otolaryngology visits a year, patients aged 15-24 makes up 7% 
and patients aged 25-44 makes up 21%5.    
In the United States the cost of a tonsillectomy varies based on your location and type of 
insurance.  There are a variety of different elements that contribute to the overall cost that 
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patients often do not factor in, including but not limited to, the pre-operative appointment, the 
post-operative appointment, if necessary antibiotics and additional any visits to deal with 
complications.  Overall, the cost for uncomplicated tonsillectomy was around $3,832, while the 
cost for tonsillectomies with complications was $6,388 for hemorrhage, $5,753 for dehydration, 
and $4,708 for pain6. 
There are a multitude of complications associated with tonsillectomies each with their 
own treatment and risks.  An important obstacle facing healthcare professionals is finding the 
best post-operative medical management to control pain with minimal side effects.  Independent 
of the technique used, substantial pain, decreased diet and reduced activity are seen. Regardless 
of the age of the patient, adequate pain control is needed in order to ensure the patient stays 
hydrated and makes a full recovery as soon as possible5.  Cox-2 inhibitors are not commonly 
used as a post-operative medication to treat pain.  Instead, patients use a combination of 
acetaminophen and ibuprofen and on rare occasions morphine to reduce pain6.  As stated 
previously, Cox-2 inhibitors work solely on the Cox-2 enzyme, which is usually responsible for 
the inflamed tissue. Cox-2 inhibitors have been indicated to treat acute pain as well as pain 
secondary to arthritis.  Consequently, they could be beneficial after a surgery where there is a 
significant amount of inflammation causing prolonged pain for the patient.   
Objective  
The objective of this selective EBM review is to determine whether or not “Are Cox-2 inhibitors 
such as celecoxib and parecoxib effective in reducing post-tonsillectomy pain?” 
 
Methods 
The studies used in this systematic review included three double blind, randomized 
controlled studies.  The population included males and females aged 2-32 undergoing an elective 
tonsillectomy with or without an adenoidectomy.  Two of the studies used varying doses of 
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celecoxib, while one study used parecoxib as their Cox-2 inhibitors.  Li X8 used intravenous 
parecoxib sodium 1 mg/kg.  Murto et al.9 used celecoxib 6 mg/kg preoperatively, followed by 3 
mg/kg twice a day for five doses.  Van Daele et al.4 used 200 mg celecoxib with a loading dose 
the night before the surgery then twice daily for ten days.  Subjects in this study were also 
instructed to supplement the study drug with hydrocodone/acetaminophen liquid as needed.  The 
population was compared to a blind placebo group in all three trials.  The outcome measured in 
the studies was the average post-operative pain using various methods.   
All three articles were published in English.   Murto9 was co-published in French.   They 
were all found in peer-reviewed journals using PubMed as the database.  All studies were found 
using keywords “tonsillectomy”, “Cox-2 inhibitor” and “pain” and were chosen based on 
relevance to the clinical question and importance of outcome to patient (POEM).  Inclusion 
criteria consisted of any randomized, controlled, and double or single blind trial published after 
2006 that used a Cox-2 inhibitor for post-tonsillectomy pain.  Studies were excluded from the 
analysis if they did not use a Cox-2 inhibitor for pain control post operatively.  All of the studies 
used P-value as the statistic to evaluate the outcomes, where the P-value is statistically 
significant if it is less than or equal to 0.05.  See Table 1 below for the specific demographics 
and characteristics of the studies included.   
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Table 1: Demographics & Characteristics of included studies  
Study Type # Pts Age 
(yrs) 
Inclusion 
Criteria 
Exclusion Criteria W/
D 
Interventions  
 Li X 8 Double blind 
placebo-
controlled 
randomized 
clinical trial  
60  3-7 Children 
aged 3-7 
years, and 
scheduled for 
elective 
tonsillectomy
, with or 
without 
adenoidecto
my under 
general 
anesthesia. 
Allergy to the 
Medications, serious 
CV disease, liver or 
kidney 
dysfunction, 
coagulation 
disorders, asthma, or 
an upper 
respiratory infection. 
0 Received IV 
Parecoxib 
sodium 1 mg_ 
kg-1 or the same 
volume of saline 
just after 
induction of 
general 
anesthesia. 
Murto9 Double Blind 
randomized 
Controlled study 
282 2-18 Children 
(age 2-18 
yr.) 
scheduled for 
elective 
surgery were 
enrolled over 
a three-year 
period 
(2009-2012). 
-Extremes BMI, 
abnormal blood 
work, moderate to 
severe OSA, any CI 
to NSAIDs, allergy 
to sulfa, risk of 
pregnancy, recently 
received 
CYP2C9 inhibitors 
or inducers, 
language barrier, 
and parent/ 
participant cognitive 
impairment. 
87 Study 
participants 
received either 
placebo or an 
adult dose 
equivalent of 
celecoxib (6 mg_ 
kg-1 ) 
preoperatively, 
followed by 3 
mg_ kg-1 twice 
daily for five 
doses 
postoperatively 
Van 
Daele 4 
Randomized 
Double Blind 
Placebo 
Controlled Trial  
17 18+ Minimum 
age of 18 
years and 
medical 
indication for 
tonsillectomy 
Hx of bleeding 
disorder, liver 
/kidney, CV disease, 
allergy/reaction to 
sulfa, NSAIDs, Cox-
2, pregnant, 
abnormal lab values, 
anyone currently 
taking celecoxib, 
anyone on warfarin 
therapy, 
uncontrolled HTN.  
0 Were randomized 
to 200 mg 
celecoxib versus 
placebo with a 
loading dose the 
night before 
surgery 
then twice daily 
for 10 days 
 
Outcomes measured 
 The outcome measured in all three studies was post-operative pain.  In Li X8 the outcome 
was measured using the Children’s Hospital of Eastern Ontario Pain Scale (CHEOPS).  The 
CHEOPS is a behavior scale used to monitor pain and discomfort in children after surgery.  In 
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Murto9 the mean “worst 24-hr pain” (WP24HR) scores were recorded on post-operative day 
(POD) 0-2 on a visual analogue scale (VAS) that was modified to reflect pain in the last 24 hours 
instead of seven days.  Zero was associated with a figure and wording and indicated no pain, 
while 100 was similarly displayed and indicated severe pain.  Children over five years old self 
reported their scores, while participants younger than five were evaluated with a postoperative 
parental pain measure modified to reflect the WP24HR by assessed twelve different behaviors to 
a checklist.  Scores were deemed clinically significant if it was greater than or equal to 10 mm on 
a VAS or a 10-20% reduction in pain.  Lastly, in Van Daele et al4 the outcome was evaluated 
using participant recoded diaries with average daily pain, maximal daily pain, and pain after 
eating.  
Results  
 In the Li X 8 randomized control trial, 60 children aged 3-7 receiving elective 
tonsillectomies were studied.  As shown in table 1, patients were excluded if they have asthma, 
an upper respiratory infection, and coagulation disorder, among others.  This was to ensure 
patient safety with anesthesia throughout the procedure and recovery period. They were 
randomly split into two equal groups (group P and group S), each similar with respect to age, 
weight, gender, surgical indication, and duration of surgery.  Patients received either intravenous 
parecoxib sodium 1mg/kg (Group P) or the same volume of saline (Group S) just after induction 
of general anesthesia.  After surgery the patients were taken to the PACU where they were 
assessed every five minutes for the first fifteen minutes and every fifteen minutes thereafter.  
Upon arrival to the surgical ward the patients were evaluated, they were also evaluated at 4, 8, 
12, 16, 20, 24 hours, with pain being estimated with the CHEOPS.  The highest pain scores were 
recorded and used in the final analysis.  If the patients CHEOPS score was less than or equal to 
8, they received morphine 25 ug/kg as a rescue medication. As shown in table 2, the CHEOPS 
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scores in the PACU of the patients in Group P were significantly lower than Group S (7 [5-8] vs. 
9 [8-11] respectively.  P=0.001).  However, in the ward, the CHEOPS scores were similar 
between the two groups.  Also, patients in Group P received a statistically significantly lower 
number of doses and amount of the rescue morphine for their pain (P=0.024).  Overall, 57% of 
participants in the parecoxib group, vs. 83% of participants in the saline group used rescue 
morphine.  Therefore, the NNT is 4 (table 3), indicating that for every 4 patients treated with 
parecoxib instead of saline, one fewer patient will experience a reduction in pain compared to 
those treated with saline. 
Table 2: The number of children receiving rescue morphine, and CHEOPS scores in patients 
who received parecoxib sodium (group P) or saline (group S) 
 Group P (n=30) Group S (n=30) Relative risk 
95% CI 
P-Value 
PACU CHEOPS 7 (5-8.3) 9 (7.8-11)  0.001 
Ward CHEOPS 4 (4-7) 5 (5-7.3)  0.29 
# of children who 
received rescue 
morphine 
17/30 (57%) 25/30 (83%) 1.5 (1-2.1) 0.024 
 
Table 3: NNT of 4, indicating for every 4 patients who received parecoxib instead of saline, one 
fewer patient will experience a reduction of pain 
CER EER Absolute risk reduction (ARR) 
 
Numbers needed to 
treat (NNT) 1/ARR 
83% 57% .26 4 
 
 In Murto et al.9 there was initially 282 children enrolled, of that 195 were included in the 
outcome analysis (celecoxib=101 and placebo=94).  Of the 141 participants initially allocated to 
the celecoxib group, 31 were lost to follow up or discontinued the intervention and of the 141 in 
the placebo group, 38 participants were lost.  The patients were randomized and the celecoxib 
group received 6 mg/kg preoperatively, followed by 3 mg/kg twice a day for five doses.  The 
control group received OraBlend and a calcium carbonate excipient, which was identical in 
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appearance and taste of the drug being studied.  WP24HR scores were reported on POD 0-2.  
There was a 95% drug compliance rate with those participants who returned their diaries.  The 
study used parent reports of pain instead of child using an intra-class correlation coefficient (ICC 
with 95% CI: 0.75-0.82).  The ICC is to measure the reliability of the measurement used. The 
data showed the celecoxib group resulted in an 11% reduction in WP24HR score averaged over 
POD 0-2 (95% CI: 0.3-14.  P=0.04).  The breakdown of POD 0-2 individually is shown in table 
3.  Furthermore, once the celecoxib was discontinued on POD 3, there was a 14% increase in 
WP24HR compared to the placebo group.  Additional, acetaminophen and morphine 
consumption on POD 0-2 was lower in the celecoxib group (P=0.03 and P=0.06 respectively). 
Since the p-value is greater than 0.05 the data is not statistically significant.  Overall, the 
incidence of adverse events between both groups was not significant, as was patient fatigue and 
parent satisfaction.   
Table 3: Parent report of post-adenotonsillectomy pain score on 100-mm VAS on POD 0-2.  
WP24HR (95%CI)) 
 Celecoxib Placebo P-value 
POD 0 50 (44-57) 62 (56-69) 0.01 
POD 1 64 (59-70) 75 (69-80) <0.01 
POD 2 63 (58-68) 64 (59-70) 0.70 
 
 Van Daele et al.4 was the only study of the three that used adults 18 or older.  There were 
17 patients selected for the study and 15 analyzed for the data (celecoxib=9 and Placebo=6).  
Two patients were lost due to discontinued intervention from the placebo group.  Patients were 
excluded from this study if they had uncontrolled hypertension, were pregnant or could be 
pregnant, on warfarin therapy, among others.  These exclusion criteria differed from the other 
studies due to the average age of the population being studied.  This study also used two different 
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methods for the tonsillectomy, the bipolar cautery (9 subjects) and the monopolar cautery (8 
subjects).  Both methods were evenly spilt between the two groups.  Each subject in the study 
provided had a self-reported journal with average daily pain, maximal daily pain, and pain after 
eating on a scale of 0-10. As well as any addition medication (acetaminophen or morphine) used 
for pain.  The pain score were generally lower, but not statistically significant in the celecoxib 
group as compared to the placebo.  There was a significantly lower amount of morphine and 
acetaminophen used in the celecoxib group (P=0.032).  The average pain on day 0 was also 
slightly lower in the celecoxib group with a P value of 0.442.   
Table 4: Maximum pain and total addition morphine use of celecoxib vs. placebo on POD 0-7.  
(Modified from the study, which showed data for POD 1-10) 
 Celecoxib n=9 Placebo n=6 95% CI 
 Day Mean Mean Lower 
Limit 
Upper 
Limit 
P Value 
 
 
Max Pain 
 
 
Day 1 5.0 6.0 -3.5 1.5 .918 
Day 
2-4 
5.1 6.0 -3.2 1.4 .918 
Day 
5-7 
4.4 5.9 -2.7 1.9 .435 
Treatment x day interaction P=0.67   
 Celecoxib n=9 Placebo n=6 95% CI 
 Day Mean Mean Lower 
Limit 
Upper 
Limit 
P Value 
 
 
Total 
Morphine 
equivalent 
 
 
Day 1 28.9 55.0 -72.9 20.7 .209 
Day 
2-4 
30.4 72.4 -81.4 -2.6 .032 
Day 
5-7 
27.8 69.7 -81.4 -2.5 .032 
Treatment x day interaction P=0.036 
 
Discussion 
 The studies presented conflicting evidence, as two out of the three showed that a Cox-2 
inhibitor could significantly help with pain post tonsillectomy with or without adenoidectomy.  
Van Daele et al4 showed that celecoxib did not significantly decrease pain post tonsillectomy, 
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however it did show a statistically significant increase in acetaminophen and morphine use in the 
placebo group compared to the celecoxib group.  Although overall pain scores were not 
significant, the data suggests patients in the placebo group may have used more pain relieving 
drugs in order to reach a common pain level with the celecoxib group.  As shown in table 1, and 
stated previous, Van Daele et al4 used a study population of 18+ that included adults, which 
could have also contributed to the varying results.  Both Li X8 and Murto9 showed that, although 
minimal, there was a clinically significant decrease in pain scores from the Cox-2 group versus 
the placebo.   
 Cox-2 inhibitors have been used to decrease pain and inflammation for many conditions, 
such as rheumatoid arthritis, osteoarthritis, juvenile idiopathic arthritis ankylosing spondylitis 
and primary dysmenorrhea3.  There were two different Cox-2 inhibitors used in the studies.  The 
most common adverse effects of celecoxib are headache, nausea, diarrhea, abdominal pain and 
insomnia10.  NSAIDs have a black box warning for increasing the risk for myocardial infraction, 
stroke, and serious stomach and intestine bleeding, ulceration or perforation.  This drug should 
only be used in pregnant women when the benefits outweigh the risks10.  Parecoxib, used in Li 
X8, is indicated for short-term treatment of postoperative pain in adults.  The most common side 
effect is nausea and should not be used in people who are allergic to any of the components, have 
had a myocardial infarction, or stroke or liver disease11. 
 There were many limitations found in this review.  In both Li X8 and Van Daele et al4 the 
population size studied was very small with 60 people in Li X and just 17 in Van Daele.  Li X8 
also discussed a few limitations of their study. Using the CHEOPS for the assessment of pain in 
children aged three to seven is controversial and does not correlate with the self-reported pain 
measures in children8.  They also talk about the use of remifentanil for the tonsillectomy, instead 
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of fentanyl, which is associated with higher postoperative pain scores, as well as the use of 
morphine at the end of surgery to reduce the need for postoperative rescue analgesics.  Lastly, 
this study talks about the limitations with the safety of the drug parecoxib and the need for 
further study to discover the optimal dose to reduce postoperative pain.  In Murto9 they discussed 
limitations such as the refusal and dropout rate due to the length of the study and the use of an 
unapproved drug to manage pain in children.  It also discussed the use of WP24HR to report pain 
as a subjective measurement that relied on the recall of the patients or the parents.  However, the 
single assessment for pain was clinically significant and was less likely to miss severe pain 
associated with recent analgesic use or by using predetermined intervals as a measurement9.  In 
all three studies another limitation was that pain could not accurately be determined due to the 
morphine and/or acetaminophen used in conjunction.  Also, the amount of the drug used and at 
what times varied from study to study. 
Conclusion 
 
 The evidence put forth in the three studies shows conflicting results, which warrants 
further research regarding the use of Cox-2 inhibitors for post-tonsillectomy pain.  Li X8 and 
Murto et al9 both concluded that the use of a Cox-2 inhibitors does reduce pain post-
tonsillectomy. Van Daele et al4 concluded there was no statistically significant decrease in pain, 
but there was a statistically significant increase in postoperative narcotic and acetaminophen use 
in the placebo group for pain.  Due to the difference in population and size of Van Daele et al4, it 
can be said that Cox-2 inhibitors does decrease pain post-tonsillectomy with or without 
adenoidectomy in children aged two to eighteen, but further testing is necessary for the adult 
population.  These studies looked at pain and co-analgesic consumption in the early stages of 
recovery, therefore, more research should be done to observe sustained pain relief and optimal 
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medication dose.  These studies should consider using the intervention for a longer period of 
time with a standard dose throughout to ensure validity of the study.  The average patient 
undergoing a tonsillectomy is in the pediatric population, consequently it is difficult to further 
study the adult population due to low number of tonsillectomies in the population. 
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